Beam Therapeutics (BEAM) Payables (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Payables data on file, last reported at $17.5 million in Q1 2026.

• On a quarterly basis, Payables rose 35.56% year-over-year to $17.5 million in Q1 2026; TTM through Mar 2026 was $17.5 million, a 35.56% increase from a year earlier, with the FY2025 full-year figure at $17.9 million, up 46.13% from the prior year.
• Payables for Q1 2026 stood at $17.5 million, down from $17.9 million in the prior quarter.
• Over the last five years, Payables for BEAM reached as high as $34.9 million in Q1 2022 and fell as low as $12.1 million in Q3 2023.
• Historically, Payables has averaged $18.7 million across 5 years, with a median of $16.5 million in 2024.
• Across the five-year window, Payables plunged 74.85% in 2022 and surged 46.13% in 2025, its largest moves.
• Year by year, Payables stood at $27.3 million in 2022, then tumbled by 54.56% to $12.4 million in 2023, then dropped by 1.18% to $12.3 million in 2024, then soared by 46.13% to $17.9 million in 2025, then slipped by 2.48% to $17.5 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $17.5 million in Q1 2026, $17.9 million in Q4 2025, and $16.0 million in Q3 2025.